[Immunocorrection in the combined treatment of patients with osteomyelitis developing following combined injuries to the maxillofacial and craniocerebral areas].
Twenty-one of the forty-two patients with osteomyelitis developing after a combined maxillofacial and craniocerebral injury were administered thymogen, an immunocorrective drug, as a component of combined therapy; immunologic indications for the prescription of such an agent were present in all these patients. Depressed T-cellular immunity was the principal disorder of the immunologic reactivity of this patient population; they also developed elevated counts of NK cells and increased interleukin synthesis by the macrophages, this reflecting a high activity of inflammation. Thymogen therapy was conducive to normalization of the immunologic and nonspecific reactivity and enhanced the treatment efficacy on the whole.
Grigoriants
L A
LA
Zuev
V P
VP
Rakhmetov
B R
BR
Eremeev
V V
VV
Abramova
Z P
ZP
Litvinova
L L
LL
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001930:Brain Injuries / Q000150:complications / Q000276:immunology / Q000628:therapy*; D003131:Combined Modality Therapy; D004151:Dipeptides; D004341:Drug Evaluation; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D008446:Maxillofacial Injuries / Q000150:complications / Q000276:immunology / Q000628:therapy*; D009104:Multiple Trauma / Q000150:complications / Q000276:immunology / Q000628:therapy*; D010019:Osteomyelitis / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D010455:Peptides / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D004151:Dipeptides; D010455:Peptides; C060736:thymogen
Immunokorrektsiia v kompleksnom lechenii bol'nykh s osteomielitom, razvivshimsia posle sochetannykh povrezhdeniĭ cheliustno-litsevoĭ i cherepno-mozgovoĭ oblasteĭ.